1
|
Yuan PP, Li M, Zhang Q, Zeng MN, Ke YY, Wei YX, Fu Y, Zheng XK, Feng WS. 2-phenylacetamide Separated from the seed of Lepidium apetalum Willd. inhibited renal fibrosis via MAPK pathway mediated RAAS and oxidative stress in SHR Rats. BMC Complement Med Ther 2023; 23:207. [PMID: 37353787 DOI: 10.1186/s12906-023-04012-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2022] [Accepted: 05/25/2023] [Indexed: 06/25/2023] Open
Abstract
BACKGROUND Renal fibrosis with Renin-angiotensin-aldosterone system (RAAS) activation and oxidative stress are one of the major complications in hypertension. 2-phenylacetamide (PA), a major active component of Lepidium apetalum Willd. (L.A), has numerous pharmacological effects. Its analogues have the effect of anti-renal fibrosis and alleviating renal injury. This study aims to explore the underlying mechanism of PA for regulating the renal fibrosis in SHR based on the MAPK pathway mediated RAAS and oxidative stress. METHODS The SHR rats were used as the hypertension model, and the WKY rats were used as the control group. The blood pressure (BP), urine volume were detected every week. After PA treatment for 4 weeks, the levels of RAAS, inflammation and cytokines were measured by Enzyme-Linked Immunosorbnent Assay (ELISA). Hematoxylin-Eosin staining (HE), Masson and Immunohistochemistry (IHC) were used to observe the renal pathology, collagen deposition and fibrosis. Western blot was used to examine the MAPK pathway in renal. Finally, the SB203580 (p38 MAPK inhibitor) antagonism assay in the high NaCl-induced NRK52e cells was used, together with In-Cell Western (ICW), Flow Cytometry (FCM), High Content Screening (HCS) and ELISA to confirm the potential pharmacological mechanism. RESULTS PA reduced the BP, RAAS, inflammation and cytokines, promoted the urine, and relieved renal pathological injury and collagen deposition, repaired renal fibrosis, decreased the expression of NADPH Oxidase 4 (NOX4), transforming growth factor-β (TGF-β), SMAD3 and MAPK signaling pathway in SHR rats. Meanwhile,,the role of PA could be blocked by p38 antagonist SB203580 effectively in the high NaCl-induced NRK52e cells. Moreover, molecular docking indicated that PA occupied the ligand binding sites of p38 MAPK. CONCLUSION PA inhibited renal fibrosis via MAPK signalling pathway mediated RAAS and oxidative stress in SHR Rats.
Collapse
Affiliation(s)
- Pei-Pei Yuan
- College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China
- The Engineering and Technology Center for Chinese Medicine Development of Henan Province, 156 Jinshui East Road, Zhengzhou, 450046, China
| | - Meng Li
- College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China
- The Engineering and Technology Center for Chinese Medicine Development of Henan Province, 156 Jinshui East Road, Zhengzhou, 450046, China
| | - Qi Zhang
- College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China
| | - Meng-Nan Zeng
- College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China
- The Engineering and Technology Center for Chinese Medicine Development of Henan Province, 156 Jinshui East Road, Zhengzhou, 450046, China
| | - Ying-Ying Ke
- College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China
- The Engineering and Technology Center for Chinese Medicine Development of Henan Province, 156 Jinshui East Road, Zhengzhou, 450046, China
| | - Ya-Xin Wei
- College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China
| | - Yang Fu
- College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China
| | - Xiao-Ke Zheng
- College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China.
- The Engineering and Technology Center for Chinese Medicine Development of Henan Province, 156 Jinshui East Road, Zhengzhou, 450046, China.
| | - Wei-Sheng Feng
- College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China.
- The Engineering and Technology Center for Chinese Medicine Development of Henan Province, 156 Jinshui East Road, Zhengzhou, 450046, China.
| |
Collapse
|
2
|
Wang MN, Cao YG, Wei YX, Ren YJ, Liu YL, Chen X, He C, Zheng XK, Feng WS. Saffloflavone, a new flavonoid from the flowers of Carthamus tinctorius L. and its cardioprotective activity. Nat Prod Res 2021; 36:3317-3323. [PMID: 33432825 DOI: 10.1080/14786419.2020.1855167] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
A new flavonoid, saffloflavone , along with six known compounds, kaempferol-3-O-rutinoside, kaempferol-3-O-sophoroside, quercetin-3-O-β-d-glucoside, quercetin-7-O-β-d-glucoside, luteolin-7-O-β-d-glucoside and kaempferol 3-O-β-d-glucoside were isolated from the flowers of Carthamus tinctorius L. All the structures were determined by interpretation of their spectroscopic data. The cardioprotective effects of all the isolates against oxidative stress of H9c2 cells induced by H2O2 were investigated. The results showed that compounds 4-6 exhibited protective effects against of H9c2 cells injury induced by H2O2.
Collapse
Affiliation(s)
- Meng-Na Wang
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, PR China;,The Engineering and Technology Center for Chinese Medicine Development of Henan Province China, Zhengzhou, PR China
| | - Yan-Gang Cao
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, PR China;,The Engineering and Technology Center for Chinese Medicine Development of Henan Province China, Zhengzhou, PR China
| | - Ya-Xin Wei
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, PR China;,The Engineering and Technology Center for Chinese Medicine Development of Henan Province China, Zhengzhou, PR China
| | - Ying-Jie Ren
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, PR China;,The Engineering and Technology Center for Chinese Medicine Development of Henan Province China, Zhengzhou, PR China
| | - Yan-Ling Liu
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, PR China;,The Engineering and Technology Center for Chinese Medicine Development of Henan Province China, Zhengzhou, PR China
| | - Xu Chen
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, PR China;,The Engineering and Technology Center for Chinese Medicine Development of Henan Province China, Zhengzhou, PR China
| | - Chen He
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, PR China;,The Engineering and Technology Center for Chinese Medicine Development of Henan Province China, Zhengzhou, PR China
| | - Xiao-Ke Zheng
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, PR China;,The Engineering and Technology Center for Chinese Medicine Development of Henan Province China, Zhengzhou, PR China
| | - Wei-Sheng Feng
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, PR China;,The Engineering and Technology Center for Chinese Medicine Development of Henan Province China, Zhengzhou, PR China
| |
Collapse
|